Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:44 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $9.58M (8.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Jan 13, 2025 | Mar 14, 2024 | Mar 16, 2023 | Mar 17, 2022 |
| Revenue | $109.2M | $6.59M | $2.23M | $5.20M | – |
| Operating expenses | $126.4M | $144.7M | $148.8M | $139.0M | $94.9M |
| Research and development | $95.7M | $107.2M | $92.7M | $97.2M | $75.6M |
| Selling, general and administrative | $24.0M | $33.2M | $34.7M | $31.9M | $19.2M |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M |
| Interest expense | – | – | $540.0K | $1.40M | $1.27M |
| Income tax | -$68.0K | $1.79M | $1.88M | $91.0K | $43.0K |
| Net income | -$9.58M | -$126.6M | -$136.7M | -$130.9M | -$95.8M |
| EPS, basic | $-0.14 | $-1.61 | $-2.30 | $-2.27 | $-2.96 |
| EPS, diluted | $-0.14 | $-1.61 | $-2.27 | $-2.27 | $-2.96 |
| Weighted shares, basic | 86.6M | 78.6M | 59.3M | 57.8M | 32.4M |
| Weighted shares, diluted | 86.6M | 78.6M | 57.8M | 57.8M | 32.4M |
| Margins and growth | |||||
| Operating margin | -15.8% | -2096.5% | -6556.9% | -2574.2% | – |
| Net margin | -8.8% | -1920.9% | -6115.1% | -2518.4% | – |
| Revenue growth, year over year | +1,556.8% | +194.8% | −57.0% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Jan 13, 2025 | Mar 14, 2024 | Mar 16, 2023 | Mar 17, 2022 |
| Cash and equivalents | $61.9M | $58.4M | $47.3M | $84.3M | $56.4M |
| Short-term investments | $55.3M | $130.9M | $125.4M | $231.2M | $166.4M |
| Total current assets | $120.8M | $194.1M | $177.0M | $319.7M | $228.2M |
| Property, plant and equipment | $50.0M | $62.1M | $71.7M | $82.8M | $58.0M |
| Intangible assets | $34.2M | $34.2M | – | – | – |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M |
| Accounts payable | $4.77M | $3.08M | $2.74M | $5.45M | $7.60M |
| Total current liabilities | $20.2M | $129.8M | $17.8M | $29.8M | $15.7M |
| Long-term debt | – | – | – | $3.74M | $8.90M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M |
| Shareholders' equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Jan 13, 2025 | Mar 14, 2024 | Mar 16, 2023 | Mar 17, 2022 |
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M |
| Capital expenditures | $848.0K | $154.0K | $13.7M | $30.6M | $45.0M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M | -$134.0M |
| Stock-based compensation | $6.84M | $12.7M | $14.6M | $10.7M | $4.66M |
| Investing cash flow | $107.5M | $47.5M | $61.1M | -$13.1M | -$298.3M |
| Financing cash flow | $173.0K | $74.6M | -$9.72M | $27.2M | $417.8M |
| Net change in cash | – | – | – | – | $30.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.3% | 192.6% | 654.2% | 205.2% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 3, 2026 | 181.1M | +109.6% | SEC |
| May 1, 2026 | 180.4M | +109.3% | SEC |
| Feb 28, 2026 | 179.7M | +108.9% | SEC |
| Nov 1, 2025 | 87.3M | +2.7% | SEC |
| Aug 1, 2025 | 86.4M | +2.0% | SEC |
| May 1, 2025 | 86.2M | +4.0% | SEC |
| Feb 28, 2025 | 86.0M | +32.7% | SEC |
| Nov 1, 2024 | 85.0M | +42.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.